NUCLIDIUM AG

Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidiums differentiated diagnostic to therapeutic approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution,...

Tracer development,diagnostic imaging,therapeutic imaging,molecular imaging,hybrid imaging,r&d,radionuclide production,precision oncology,and targeted radiotherapy

Nuclidium ag operates in the Biotechnology research industry.

Nuclidium ag's revenue is 11m - 100m

Nuclidium ag has 11 - 50 employees.